Virginia F. Borges

13.7k total citations
227 papers, 7.2k citations indexed

About

Virginia F. Borges is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Virginia F. Borges has authored 227 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 178 papers in Oncology, 79 papers in Pulmonary and Respiratory Medicine and 59 papers in Cancer Research. Recurrent topics in Virginia F. Borges's work include Breast Cancer Treatment Studies (54 papers), HER2/EGFR in Cancer Research (52 papers) and Cancer Risks and Factors (50 papers). Virginia F. Borges is often cited by papers focused on Breast Cancer Treatment Studies (54 papers), HER2/EGFR in Cancer Research (52 papers) and Cancer Risks and Factors (50 papers). Virginia F. Borges collaborates with scholars based in United States, Canada and Australia. Virginia F. Borges's co-authors include Pepper Schedin, Traci R. Lyons, Ann H. Partridge, Steven E. Come, Lidia Schapira, Kathryn J. Ruddy, Rulla M. Tamimi, Shari Gelber, Sonali Jindal and Shoshana M. Rosenberg and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Virginia F. Borges

220 papers receiving 7.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Virginia F. Borges United States	48	4.8k	1.8k	1.4k	1.4k	1.2k	227	7.2k
Carey K. Anders United States	45	5.4k 1.1×	2.6k 1.4×	2.0k 1.4×	2.8k 2.0×	555 0.5×	211	8.7k
Pauline Wimberger Germany	43	3.4k 0.7×	1.4k 0.8×	2.3k 1.6×	1.1k 0.8×	1.1k 1.0×	311	8.0k
Gloria Broadwater United States	42	3.1k 0.6×	1.8k 1.0×	1.2k 0.8×	1.0k 0.7×	476 0.4×	182	6.2k
Judith R. Kroep Netherlands	45	3.1k 0.6×	1.5k 0.8×	1.6k 1.1×	1.8k 1.3×	904 0.8×	215	7.0k
David J. Vaughn United States	48	4.7k 1.0×	919 0.5×	2.3k 1.6×	2.4k 1.7×	652 0.6×	262	10.8k
Vittorina Zagonel Italy	52	5.3k 1.1×	1.4k 0.8×	2.0k 1.4×	2.4k 1.7×	1.2k 1.0×	467	11.4k
Francesco Cognetti Italy	46	5.0k 1.0×	1.7k 1.0×	2.4k 1.7×	2.3k 1.7×	454 0.4×	221	8.5k
Dongyun Yang United States	45	4.3k 0.9×	1.3k 0.7×	2.6k 1.8×	1.6k 1.2×	847 0.7×	313	7.9k
Curtis A. Pettaway United States	52	2.9k 0.6×	1.4k 0.8×	2.2k 1.6×	3.3k 2.4×	978 0.8×	264	10.1k
Lucia Del Mastro Italy	48	5.3k 1.1×	2.5k 1.4×	1.2k 0.8×	1.7k 1.3×	362 0.3×	332	8.7k

Countries citing papers authored by Virginia F. Borges

Since Specialization

Citations

This map shows the geographic impact of Virginia F. Borges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia F. Borges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia F. Borges more than expected).

Fields of papers citing papers by Virginia F. Borges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia F. Borges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia F. Borges. The network helps show where Virginia F. Borges may publish in the future.

Co-authorship network of co-authors of Virginia F. Borges

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia F. Borges. A scholar is included among the top collaborators of Virginia F. Borges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia F. Borges. Virginia F. Borges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shagisultanova, Elena, et al.. (2025). Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 25(7). 643–649.e1.

Sella, Tal, Shoshana M. Rosenberg, Gregory J. Kirkner, et al.. (2024). Breastfeeding experiences among young breast cancer survivors: A survey study. Cancer. 131(1). e35585–e35585. 3 indexed citations

Sella, Tal, Yue Zheng, Shoshana M. Rosenberg, et al.. (2023). Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. npj Breast Cancer. 9(1). 31–31. 3 indexed citations

Lipsyc-Sharf, Marla, Esha Jain, Laura C. Collins, et al.. (2023). Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. JCO Precision Oncology. 7(7). e2300076–e2300076. 3 indexed citations

Sella, Tal, Shoshana M. Rosenberg, Shari Gelber, et al.. (2023). Abstract P5-08-06: Breastfeeding in Survivors of Early Breast Cancer. Cancer Research. 83(5_Supplement). P5–8. 2 indexed citations

Collins, Laura C., Yue Zheng, Nabihah Tayob, et al.. (2023). Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC).. Journal of Clinical Oncology. 41(16_suppl). 505–505. 1 indexed citations

Lin, Nancy U., Virginia F. Borges, Manish R. Patel, et al.. (2023). 382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. Annals of Oncology. 34. S338–S338. 7 indexed citations

Sella, Tal, Geoffrey Fell, Peter G. Miller, et al.. (2022). Patient perspectives on testing for clonal hematopoiesis of indeterminate potential. Blood Advances. 6(24). 6151–6161. 8 indexed citations

Shagisultanova, Elena, et al.. (2021). Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Research and Treatment. 187(3). 883–891. 2 indexed citations

10.

Schapira, Lidia, Yue Zheng, Shari Gelber, et al.. (2021). Trajectories of fear of cancer recurrence in young breast cancer survivors. Cancer. 128(2). 335–343. 69 indexed citations

11.

Guo, Qiuchen, Duanchen Sun, Alexander Barrett, et al.. (2021). Mammary collagen is under reproductive control with implications for breast cancer. Matrix Biology. 105. 104–126. 22 indexed citations

12.

Pak, Linda M., Shoshana M. Rosenberg, Kathryn J. Ruddy, et al.. (2020). Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. Breast Cancer Research and Treatment. 186(3). 815–821. 5 indexed citations

13.

Poorvu, Philip D., Shari Gelber, Shoshana M. Rosenberg, et al.. (2019). Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. Journal of Clinical Oncology. 38(7). 725–733. 48 indexed citations

14.

Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations

15.

Greene, Lisa I., Tullia C. Bruno, Jessica L. Christenson, et al.. (2018). A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. Molecular Cancer Research. 17(1). 131–139. 103 indexed citations

16.

Moulder, Stacy L., Virginia F. Borges, Tara Baetz, et al.. (2017). Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clinical Cancer Research. 23(14). 3529–3536. 111 indexed citations

17.

Goddard, Erica T., Ryan C. Hill, Travis Nemkov, et al.. (2016). The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis. Cancer Discovery. 7(2). 177–187. 39 indexed citations

18.

Collins, Laura C., Shari Gelber, Jonathan D. Marotti, et al.. (2015). Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. The Oncologist. 20(7). 713–718. 15 indexed citations

19.

Nooruddin, Zohra, Chad G. Rusthoven, Anthony Elias, et al.. (2014). Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro-Oncology. 16(7). 1006–1009. 45 indexed citations

20.

Jacobsen, Britta M., J. Chuck Harrell, Paul Jedlicka, et al.. (2006). Spontaneous Fusion with, and Transformation of Mouse Stroma by, Malignant Human Breast Cancer Epithelium. Cancer Research. 66(16). 8274–8279. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact